Engrave Wealth Partners LLC Purchases 28 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Share on StockTwits

Engrave Wealth Partners LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 162 shares of the medical research company’s stock after buying an additional 28 shares during the period. Engrave Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $58,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Enterprise Bank & Trust Co increased its holdings in shares of Thermo Fisher Scientific by 1.5% in the second quarter. Enterprise Bank & Trust Co now owns 7,231 shares of the medical research company’s stock valued at $2,620,000 after purchasing an additional 105 shares during the last quarter. FDx Advisors Inc. grew its stake in shares of Thermo Fisher Scientific by 3.2% in the first quarter. FDx Advisors Inc. now owns 6,241 shares of the medical research company’s stock valued at $1,770,000 after acquiring an additional 193 shares in the last quarter. Fulton Bank N.A. grew its stake in shares of Thermo Fisher Scientific by 7.8% in the first quarter. Fulton Bank N.A. now owns 5,125 shares of the medical research company’s stock valued at $1,454,000 after acquiring an additional 371 shares in the last quarter. APG Asset Management N.V. grew its stake in shares of Thermo Fisher Scientific by 11.3% in the first quarter. APG Asset Management N.V. now owns 359,073 shares of the medical research company’s stock valued at $101,833,000 after acquiring an additional 36,357 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 13.3% in the first quarter. Nuveen Asset Management LLC now owns 1,900,512 shares of the medical research company’s stock valued at $538,985,000 after acquiring an additional 223,193 shares in the last quarter. Hedge funds and other institutional investors own 87.51% of the company’s stock.

Several research firms recently commented on TMO. Cowen restated a “buy” rating and issued a $380.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Needham & Company LLC upped their price objective on shares of Thermo Fisher Scientific from $383.00 to $415.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Co upped their price objective on shares of Thermo Fisher Scientific from $300.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 21st. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $365.00 to $390.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Finally, SVB Leerink upped their price objective on shares of Thermo Fisher Scientific from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, April 23rd. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $357.42.

In related news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $348.00, for a total value of $870,000.00. Following the completion of the transaction, the chief financial officer now owns 37,989 shares in the company, valued at approximately $13,220,172. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $349.89, for a total transaction of $6,997,800.00. Following the completion of the transaction, the chief executive officer now owns 294,946 shares of the company’s stock, valued at approximately $103,198,655.94. The disclosure for this sale can be found here. Insiders sold 97,500 shares of company stock valued at $33,044,350 in the last three months. Company insiders own 0.44% of the company’s stock.

Shares of TMO stock traded up $8.53 on Tuesday, reaching $387.46. The company had a trading volume of 859,335 shares, compared to its average volume of 1,860,439. The stock has a market capitalization of $149.66 billion, a PE ratio of 42.48, a price-to-earnings-growth ratio of 2.40 and a beta of 1.04. The company has a quick ratio of 1.69, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a one year low of $250.21 and a one year high of $395.00. The business’s 50-day moving average is $355.28 and its 200 day moving average is $328.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, topping analysts’ consensus estimates of $2.79 by $0.15. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6.18 billion. Thermo Fisher Scientific had a net margin of 14.31% and a return on equity of 17.25%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.81 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 12.73 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.22 dividend. The ex-dividend date is Monday, September 14th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.23%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.13%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.